Ajmani AK, Agrawal A, Prasad BLN, et al. - In Indian patients with uncontrolled T2D, researchers tested the safety and effectiveness of evogliptin compared with sitagliptin, when added to background metformin therapy. Overall, 184 individuals with uncontrolled T2D (7% ≤ HbA1c < 10%) receiving ≥ 8 weeks of stable metformin monotherapy (≥ 1 g/day), were randomized to obtain add-on treatment (evogliptin 5 mg or sitagliptin 100 mg) for 24 weeks. Data reported that mean reductions in HbA1c at 12 weeks in evogliptin- and sitagliptin-treated patients were −0.37 (1.06) and –0.32 (1.14), respectively. In HbA1c reduction, evogliptin was non-inferior to sitagliptin. It improved glycemic control effectively and was well tolerated in T2D patients inadequately controlled by metformin alone. Mild treatment-emergent adverse events occurred in this analysis.